ArticleNature biotechnology2026
Adaptive model-guided protein evolution with sparse data optimizes compact eukaryotic genome editors.
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Efficient protein engineering is constrained by vast sequence space and limited experimental throughput, particularly for protein families that lack large mutational datasets. Here we combine Fanzor2 (Fz2) ortholog discovery, ωRNA scaffold engineering and EvoMax, a model-guided prioritization strategy for sparse-data engineering of compact eukaryotic Fz2 nucleases. EvoMax integrates iterative experimental profiling with Gaussian process regression, protein language models and inverse folding to navigate complex sequence-to-fitness landscapes. Applied to eukaryotic Fz2 nucleases, this strategy yielded a high-performance variant, FanzMAX v3-hLa, achieving up to 97% editing efficiency at the best-performing endogenous locus and a mean editing efficiency of ~33% across 19 endogenous loci, outperforming the established compact genome editors enNlovFz2 and enCnCas12f1 by more than 2.6-fold. In vivo editing of hPCSK9 in humanized mice supported the translational potential of optimized Fz2 editors. Together, these results establish EvoMax as an integrated strategy for engineering compact eukaryotic Fz2 genome editors and identify FanzMAX v3-hLa as a high-efficiency programmable nuclease for mammalian genome editing.
Identifiers
42637959What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.